A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.

The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophilic gelling polymer, and an effervescent system.

The present invention relates to a solid pharmaceutical preparation and a preparation method therefor. Specifically, disclosed are a solid pharmaceutical preparation that comprises an orexin receptor antagonist compound and a preparation method therefor, the solid pharmaceutical preparation comprising an active ingredient of a compound represented by formula I, a filler, a binder, a disintegrant, and a lubricant. The solid pharmaceutical preparation has good dissolution, stability and in vivo bioavailability.

##STR00001##

Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof ##STR00001##

Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a Musan box (Sphallerocarpus gracilis) extract or a fraction thereof as an active ingredient.

The present invention relates to Rapid melt granules prepared by encapsulation and complexation processes. The present invention specifically relates to Rapid melt granules prepared by novel process of particulate coating comprising the steps of encapsulation of active ingredient with encapsulation polymer and/or pore former, drying, blending, optionally polymer coating, drying before blending and filling into sachets or compressing into tablets. The present invention more specifically relates to Rapid melt granules prepared by novel process of complexation comprising the steps of complexation of active ingredient with sulfonated polymers of ion exchange resin, drying, blending, optionally polymer coating, drying before blending and filling into sachets or compressing into tablets.

The present invention relates to a function of PHF20 (PHD finger protein 20) in a myogenic differentiation mechanism and, more particularly, to a use of a PHF20 gene expression inhibitor or a PHF20 protein activity inhibitor. The PHF20 gene expression inhibitor or the PHF20 protein activity inhibitor according to the present invention promotes muscle differentiation in vitro and in vivo, and thus can be utilized in various ways in the field of prevention, improvement or treatment of diseases caused by muscle loss.

The disclosure describes an injection molding process for coating a tablet core to produce a coated pharmaceutical tablet, wherein the injection-molded coating is substantially continuous (e.g., completely covers the tablet core with no openings), and describes the resulting coated pharmaceutical tablet. The disclosure describes compositions for coatings and tablet cores and equipment suitable for performing the process.

Temperature-stable, gastric-resistant formulation suitable for oral and sustained delivery of proteins, including insulin, and for nucleic acids (e.g., DNA, RNA), and related methods of making and use are described. In an embodiment, The thermostable and acid-stable pharmaceutical composition includes an inclusion complex, where the inclusion complex includes a lipophilic active pharmaceutical ingredient-carrier ionic association complex encapsulated in a β-cyclodextrin or derivative thereof. In an embodiment, the pharmaceutical composition ion-pair complex encapsulated in the β-cyclodextrin or derivative thereof is in the form of a convenient dissolvable tablet dosage form.